Bibliography for: "Over two-thirds of adult Americans trust their doctors to choose the best drugs for them, despite the aggressive marketing they receive from pharmaceutical companies - Drug Cost Studies in Brief - Brief Article"

"Over two-thirds of adult Americans trust their doctors to choose the best drugs for them, despite the aggressive marketing they receive from pharmaceutical companies - Drug Cost Studies in Brief - Brief Article". Drug Cost Management Report. FindArticles.com. 14 Dec, 2009. http://findarticles.com/p/articles/mi_m0NKV/is_2_4/ai_97592362/

Drug Cost Management Report

View more issues:

Articles in Feb, 2003 issue of Drug Cost Management Report

• Pharmacare's generic substitution pilot nets savings, goodwill
• Over two-thirds of adult Americans trust their doctors to choose the best drugs for them, despite the aggressive marketing they receive from pharmaceutical companies - Drug Cost Studies in Brief - Brief Article
• Members of BlueCross BlueShield of South Carolina and Companion HealthCare now have access to a free, online drug information and cost comparison tool—My Pharmacy Manager - Company News in Brief - Brief Article
• The Blue Cross and Blue Shield plans market for PBM services
• First Health Services has been re-awarded the contract to administer the Pennsylvania PACE and PACENET pharmacy benefit program for senior citizens through 2008 - Contracts and Alliances in Brief - Brief Article
• Coming in March
• Re-engineering therapeutic intervention programs for maximum client value
  by Tim Watson
• Direct-to-consumer advertising for prescription drugs influences consumers to seek more information, according to the National Consumers League - DTC - NCL - Drug Cost Studies in Brief - Brief Article
• A controversial plan to limit prescription drug coverage for Medicaid recipients in Louisiana has been postponed - State News in Brief - Brief Article
• PBMs catch a break from the feds: GAO report favorable
• Blue Cross Blue Shield of Massachusetts is launching an electronic prescribing pilot in conjunction with Express Scripts, Medix Resources, Inc., and PocketScript - BCBSMA - Contracts and Alliances in Brief - Brief Article
• The FDA has established the Office of Combination Products , a new office created to streamline the processing of complex drug-device, drug-biologic, and device-biologic combination products - OCP - Government News in Brief - Brief Article
• Two out of three migraine sufferers have delayed taking their medications or skipped doses because of concern over side effects - Drug Cost Studies in Brief - Brief Article
• A significant number of women stopped taking hormone replacement therapy products after learning of the possible long-term effects - HRT - Product News in Brief - Brief Article
• WellPoint markets generics to physicians and members
• The Hartford Financial Services Group, Inc. has selected AdvancePCS SpecialtyRx and MIM Corporation's BioScrip® specialty pharmacy to provide stop loss customers with access to favorable pricing for high-cost injectable medications - Contracts and Al
• RxHub has entered into four new strategic partnerships for its medication prescribing technology and specifications - Company News in Brief - Brief Article
• 2002 biotech drug launches
• 2003 may see a decline in the number of prescriptions for antihypertensive drugs - Drug Cost Studies in Brief - Brief Article
• Pfizer Inc. has received FDA approval to market Relpax for the treatment of acute migraine - eletriptan hydrobromide - Product News in Brief - Brief Article
• NY state proposed Medicaid cuts threaten recipients, biotech industry
• CVS Corporation has entered into a settlement agreement with the Attorneys General of a number of states with respect to allegations related to billing practices concerning "partial-fill" prescriptions - Legal News in Brief - Brief Article
• Abbott Laboratories has announced the launch of the HUMIRA Medicare Assistance Program, a drug access program that will provide seniors with its newly approved rheumatoid arthritis drug, HUMIRA™ - RA - Drug Cost Strategies in Brief - Brief Article
• AstraZeneca has announced that it will seek a bipolar disorder indication for Seroquel - quetiapine - Product News in Brief - Brief Article